載入...
Management of a 75-Year-Old Lady with Refractory Chronic Myelogenous Leukemia
Chronic myelogenous leukemia (CML) is a hematopoietic disorder caused by the BCR/ABL gene or Philadelphia chromosome. The first Food and Drug Administration (FDA)-approved tyrosine kinase inhibitor for treatment of CML was imatinib in 2001. Since then, multiple therapies, such as nilotinib, dasatini...
Na minha lista:
| 發表在: | Case Rep Oncol |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
S. Karger AG
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7265745/ https://ncbi.nlm.nih.gov/pubmed/32518550 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000506895 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|